Abstract: Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.
Abstract: A method of preparing an IgA rich preparation comprising exposing a plasma fraction to an amino acid, organic salt or inorganic salt with optional chromatographic treatment yielding a product suitable for use in medical conditions treatable with IgA.
Type:
Grant
Filed:
December 10, 1991
Date of Patent:
November 2, 1993
Assignee:
Alpha Therapeutic Corporation
Inventors:
Yahiro Uemura, Sunnie Park, Raja R. Mamidi, Charles M. Heldebrandt
Abstract: The present invention relates to the peptides consisting of 25-50 amino acid residues and comprising the following peptide sequence:Leu-Met-His-Asn-Leu-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His -His-Leu-Ile-Ala-Glu-Ile (I)and amides and salts thereof. The peptides have stronger inhibitory activity against hPTH when compared with conventional inhibitors, and therefore, they are expected to be useful for the treatment of various diseases associated with calcium or phosphoric acid metabolism such as hypercalcemia and osteoporosis, or diseases associated with PTH and PTHrP.
Abstract: Preparation process for a protein comprising at least one intramolecular disulphide bridge, and optionally one or more additional cysteines, comprising the oxidation of the corresponding reduced recombinant protein using an oxidizing agent and characterized in that an aqueous solution of the reduced protein is reacted at a pH of less than 5.0.
Type:
Grant
Filed:
May 6, 1992
Date of Patent:
October 12, 1993
Assignee:
Roussel Uclaf
Inventors:
Pierre Y. Abecassis, Jacques Leclaire, Philippe Riberon
Abstract: A composition is disclosed which comprises a solution of human serum albumin essentially free of chemicals used in processing. The preparation is also essentially free of metals such as aluminum. The composition is 100% pure by cellulose acetate electrophoresis and is essentially monomeric when tested by high pressure liquid chromatography. The turbidity is less than 5 N.T.U. (National Turbidity Units). This preparation has a substantially longer shelf life and remains biologically active longer than products currently available. The novelty of this product is also such that it does not leach metallic substances such as aluminum from its closure. Novel applications of process methodology are taught in the preparation of this composition and a novel preparation results from essentially non hemoglobin containing albumin sources such as Source Plasma (Human).
Abstract: A method for separating phytate and manganese from protein and dietary fiber involves treatment of an aqueous slurry of phytate-containing material at a low pH with insoluble alumina. In a batch treatment process the pH of the solution is increased, leaving phytate units attached to the alumina while freeing the protein and dietary fiber. In a column treatment process, the column containing alumina is rinsed, after the low pH treatment, with dilute acid and water to recover the protein and/or dietary fiber. This method may be employed either during the manufacture of protein and fiber isolates from flour or flakes, or for removing phytate from commercially available protein and fiber commodities. The spent alumina may be readily regenerated and reused. A method of separating manganese from rice protein using this same technology is also disclosed.
Type:
Grant
Filed:
December 20, 1991
Date of Patent:
September 28, 1993
Assignee:
Abbott Laboratories
Inventors:
Terrence B. Mazer, Christy A. Nardelli, Arthur J. C. L. Hogarth, Andre Daab-Krzykowski
Abstract: Protein conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the polypeptide compositions efficiently.
Type:
Grant
Filed:
August 31, 1990
Date of Patent:
September 7, 1993
Assignee:
NeoRx Corporation
Inventors:
Alan R. Fritzberg, Sudhakar Kasina, Ananthachari Srinivasan, Daniel S. Wilbur
Abstract: The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention specifically provides somatostatin, somatostatin derivatives, somatostatin analogues or peptides that bind to the somatostatin receptor and contain at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form that are directly labeled with technetium-99m and that can be targeted to specific sites within a mammalian body for imaging.
Type:
Grant
Filed:
September 10, 1991
Date of Patent:
July 6, 1993
Assignee:
Diatech, Inc.
Inventors:
Richard T. Dean, John Lister-James, Scott Buttram
Abstract: An agent for tyrosinase inhibition which contains the effective quantity of enzymatic hydrolyzates of milk proteins, having a decomposition rate from 6% to 55% as expressed by the percentage of formol nitrogen to total nitrogen.
Abstract: The invention relates to a method for labeling substances with--in particular radioactive--technetium or rhenium isotopes with the aid of N-substituted or C-substituted macrocyclic amine derivatives of the formula I and/or II ##STR1## in which R.sup.1 -R.sup.7, Y, m, n, o, p, f, g, h, i and j have the stated meanings, and to the use of these labeled substances, especially in medical diagnosis.
Type:
Grant
Filed:
August 25, 1988
Date of Patent:
June 15, 1993
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Karl-Heinz Bremer, Ludwig Kuhlmann, Michael Magerstadt, Alexander Schwarz, Axel Steinstrasser
Abstract: The present invention provides a metal ion scavenging procedure and antibody compositions for radioimmunoscintigraphy and cytotoxic radioimmunotherapy having chelator concentrations of greater than about 10.sup.-4 M which are optimized with respect to their metal binding capacity such that highly efficient labelling of the antibody is achieved in a simple one step procedure using readily available sources of radiometal ions.
Abstract: An acid system for acidizing wells contains corrosion inhibitor additives which consist essentially of a metal selected from antimony and antimony mixtures, a quaternary compound, and a surfactant. The corrosion inhibitor is free of toxic acetylenic compounds.
Type:
Grant
Filed:
February 12, 1992
Date of Patent:
May 11, 1993
Assignee:
Exxon Chemical Patents, Inc.
Inventors:
Dennis A. Williams, Phyllis K. Holifield, James R. Looney, Lee A. McDougall
Abstract: Disclosed is a method of quantifying molecules in biological substances, comprising:a. selecting a biological host in which radioisotopes are present in concentrations equal to or less than those in the ambient biosphere,b. preparing a long-lived radioisotope labeled reactive chemical specie,c. administering said chemical specie to said biological host in doses sufficiently low to avoid significant overt damage to the biological system thereof,d. allowing a period of time to elapse sufficient for dissemination and interaction of said chemical specie with said host throughout said biological system of said host,e. isolating a reacted fraction of the biological substance from said host in a manner sufficient to avoid contamination of said substance from extraneous sources,f. converting said fraction of biological substance by suitable means to a material which efficiently produces charged ions in at least one of several possible ion sources without introduction of significant isotopic fractionation, and,g.
Type:
Grant
Filed:
April 26, 1991
Date of Patent:
May 11, 1993
Assignee:
Regents of the University of California
Inventors:
Kenneth W. Turteltaub, John S. Vogel, James S. Felton, Barton L. Gledhill, Jay C. Davis, Larry H. Stanker
Abstract: There are provided paramagnetic compounds comprising a paramagnetic metal species chelated by a chelating moiety bound by an amide group to a linker group itself bound by an ester group to a macromolecule, wherein said linker group provides a carbon chain of at least 2 atoms between said amide group and said ester group. The novel compounds are particularly suitable as contrast agents, e.g. in magnetic resonance imaging.
Abstract: The present invention is directed to radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5.alpha.-epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors.The radioimaging agent of the present invention has the following formula: ##STR1## wherein I is selected from the group consisting of .sup.123 I and .sup.125 I; and where R is alkyl, cycloalkylloweralkyl or allyl.
Type:
Grant
Filed:
June 14, 1991
Date of Patent:
May 4, 1993
Assignee:
The United States of America as represented by the Department of Health & Human Services.
Inventors:
Brian R. de Costa, Michael J. Iadarola, Kenner C. Rice, Richard B. Rothman, Karen F. Berman
Abstract: An encapsulated breaker chemical composition used in a fracturing process in an oil or gas stimulation operation which comprises: (a) a breaker chemical; (b) a water soluble sealing layer, such as urea, having a thickness within the range of about 1 to about 30 microns deposited on the surface of said breaker chemical and encapsulating said breaker chemical; and (c) a pinhole free coating of a neutralized sulfonated elastomeric polymer of about 2 to about 80 microns thick deposited onto the surface of the coated breaker chemical, wherein said neutralized sulfonated polymer encapsulates the breaker chemical and is permeable to the breaker chemical.
Type:
Grant
Filed:
January 3, 1992
Date of Patent:
April 20, 1993
Assignee:
Exxon Research and Engineering Company
Inventors:
Lee A. McDougall, John C. Newlove, Pacifico V. Manalastas, Evelyn N. Drake
Abstract: The invention relates to a method of detecting an Fc receptor-expressing tumor site in an individual by administering to the individual a diagnostically effective amount of detectably-labeled non-specific immunoglobulin or Fc or Fc' fragment thereof, wherein the immunoprotein substantially accumulates at the site when the site bears such a tumor. By using a therapeutically-labeled specific or non-specific immunoglobulin or Fc or Fc' fragment thereof, the tumor may be treated therapeutically.
Type:
Grant
Filed:
July 16, 1991
Date of Patent:
April 6, 1993
Assignee:
The General Hospital Corporation
Inventors:
H. William Strauss, Robert H. Rubin, Ban An Khaw, Faina Shtern